----- SPECIAL EDITION -----
European Association for the Study of Diabetes (EASD) 2024
PICTURE CREDIT: EASD – European Association for the Study of Diabetes e.V.
The 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) took place last week in Madrid, Spain, with thousands of healthcare professionals attending the annual event both in-person and online.
The conference programme delivered a range of daily sessions, with a mix of plenaries, symposiums and workshops.
A variety of speakers from around the world presented the latest developments in diabetes treatment and discussed the most pressing and controversial areas relating to management.
The results from clinical trials evaluating once weekly insulin efsitora alfa in adults with type 2 diabetes using basal insulin for the first time have been released.
Eli Lilly and Company has also published how once weekly insulin efsitora alfa impacts those who have switched from daily basal insulin injections.
A new drug delivery system can cut the dosing schedule for semaglutide to just once a month, according to new research presented last week at EASD 2024.
Lead author Dr Claire Mégret, from ADOCIA, said: “Glucagon-like peptide-1 agonist (GLP-1) drugs have transformed type 2 diabetes care, but weekly injections can be burdensome for people.
Individuals who received a once-a-day oral weight loss drug lost up to 13 per cent of their body weight over three months, according to research presented at EASD 2024.
Amycretin, which is being developed by the Danish pharmaceutical company Novo Nordisk A/S, mimics the action of two peptide hormones in one single molecule.
PolTREG has presented positive long-term data for its cell therapy, PTG-007, showing that the therapy induced clinical remission for type 1 diabetes for up to 12 years. To read more, click here.
Amycretin, a dual pathway, oral weight loss drug, led to roughly 13 per cent body weight loss in participants with overweight or obesity according to data presented at EASD 2024. To read more, click here.
Individuals who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, the Annual Meeting of the European Association for the Study of Diabetes has heard. To read more, click here.
Weight loss interventions could reduce the risk of severe cases of flu and other infections in people with diabetes, new research presented at the European Association for the Study of Diabetes (EASD) has suggested. To read more, click here.
Advances in early screening for type 1 diabetes and associated autoimmune diseases were shared last week at the European Association for the Study of Diabetes (EASD) 2024.
A pioneering study, named the DiaUnion Project, used innovative antibody detection technologies to identify type 1 diabetes, celiac disease and autoimmune thyroid disease — known collectively as the TRIAD diseases.
The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine for type 2 diabetes.
Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight loss indicates that greater weight loss, better β-cell function, and a greater decrease in low-density lipoprotein cholesterol during the first year of tirzepatide therapy are the most robust predictors of better long-term outcomes.
Semaglutide can prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function.
This is according to new research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD) in Madrid.
Machine learning excels at automatically identifying complex patterns and relationships in continuous glucose monitoring (CGM) systems, research presented at EASD has shown.
Findings reported at a Roche media event highlighted that AI-based glucose prediction can outperform traditional modelling approaches at predicting glucose levels.
New research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes in Madrid highlights the potential of using voice analysis to detect undiagnosed type 2 diabetes cases.
The study used on average 25 seconds of people’s voices along with basic health data including age, sex, body mass index (BMI), and hypertension status, to develop an AI model that can distinguish whether an individual has type 2 diabetes or not, with 66 per cent accuracy in women and 71 per cent accuracy in men.
Restricting the eating window to eight hours a day significantly improves blood glucose control in adults at risk of type 2 diabetes, irrespective of whether it is earlier or later in the day.
This is according to a randomised crossover trial presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD) in Madrid.
People who stay up late have a higher BMI and larger waists, and are almost 50 per cent more likely to develop type 2 diabetes than those who go to bed earlier. To read more, click here.
Individuals with type 2 diabetes are more likely to develop asthma – and vice versa, according to an analysis of data presented at this year’s EASD. To read more, click here.
A new guideline aimed at improving the management and monitoring of diabetic retinopathy has been released. To read more, click here.
Insulin resistance is associated with 31 different diseases, a study presented at EASD 2024 in Madrid has found. To read more, click here.
Despite high use of continuous glucose monitoring and insulin pump therapy, fear of hypoglycaemia remains a significant barrier to physical activity and exercise for adults with type 1 diabetes.
New research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD) suggests that if exercise and diabetes management are discussed in the clinic, the fear of hypoglycaemia could be reduced.
A pioneering tech company at the forefront of diabetes monitoring has been shortlisted for two Wales Science, Technology, Engineering and Maths (STEM) Awards 2024. To read more, click here.
Treatment with GLP-1 receptor agonists (GLP-1s) in people with type 2 diabetes was associated with a reduced risk of ocular hypertension and glaucoma compared with metformin treatment. To read more, click here.
Researchers found that higher levels of interleukin-6 were associated with increased risk of obesity-related cancers in people who have recently been diagnosed with type 2 diabetes. To read more, click here.
People with chronic diabetic foot ulcers could soon have a new way to treat their wounds for faster healing and fewer hospital stays, according to a team of researchers. To read more, click here.
There was a time when I used to look at the Royal College of Physicians with a massive amount of deference and marvel at their 'royalty'. It felt like this organisation which was just amazing, somewhat ethereal. For many of us growing up in India, the MRCP meant a heck of a lot, and to be honest it still does to a lot of people. To read more, click here.
Bringing you the latest jobs from around the country within the field of diabetes.
Diabetes Specialist Nurse – Norfolk Community Health and Care NHS Trust
Community Diabetes Nurse – NELFT North East London Foundation Trust
Diabetes Specialist Midwife – Barts Health NHS Trust
Consultant in Children and Young People’s Diabetes – University College London Hospitals NHS Foundation Trust
